PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed performance with strong revenue growth and improved gross margins, but significant concerns arise from increased losses, higher operating expenses, and weak Q4 handpiece sales. While guidance for 2026 shows potential, the immediate impact of discontinuing bulk discounts, increased ASP, and the sales force realignment creates uncertainty. The Q&A session highlights management's confidence in future growth but lacks concrete evidence for some claims. Given the market cap and these factors, a negative stock price reaction is expected.
Key Financial Performance
Total revenue for Q4 2025 $76.4 million, representing 12% year-over-year growth. The growth was driven by increased procedure volumes and higher average selling prices for handpieces.
U.S. revenue for Q4 2025 $66.6 million, reflecting 10% growth compared to the prior year period. This growth was attributed to increased procedure volumes and system placements.
U.S. procedures in Q4 2025 12,200 procedures, representing approximately 69% year-over-year growth. The growth was due to higher adoption and utilization of the company's systems.
Handpieces sold in Q4 2025 9,400 units at an average selling price of $3,340, reflecting a 5% price increase compared to Q3 2025. The increase in price was due to the elimination of bulk purchase discounts.
Other consumable revenue for Q4 2025 $2.3 million, contributing to total U.S. handpiece and consumable revenue of $34 million, which represented 16% growth compared to Q4 2024.
U.S. robot placements in Q4 2025 65 new HYDRO systems sold, leading to an installed base of 718 systems, a 42% increase compared to year-end 2024.
Total U.S. system revenue for Q4 2025 $27.6 million, comparable to the prior year period, with systems sold at an average price of $425,000.
International revenue for Q4 2025 $9.8 million, representing year-over-year growth of 25%, driven by increased adoption in international markets.
Gross margin for Q4 2025 60.6%, compared to 64% in Q4 2024. The decline was due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action.
Full-year 2025 gross margin 63.7%, compared to 61.1% in 2024, reflecting improved operational efficiencies despite the Q4 decline.
Operating expenses for Q4 2025 $77.4 million, up from $63.4 million in Q4 2024. The increase was due to investments in commercial expansion, innovation, and clinical trials.
Net loss for Q4 2025 $29.8 million, compared to a net loss of $18.9 million in Q4 2024. The higher loss was driven by increased operating expenses.
Adjusted EBITDA for Q4 2025 Loss of $19 million, compared to a loss of $10.3 million in Q4 2024, due to higher operating expenses.
Cash, cash equivalents, and restricted cash as of December 31, 2025 $285 million, providing a strong balance sheet to support strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HYDRO system placements: 65 new HYDRO systems sold in Q4 2025, increasing the installed base to 718 systems, a 42% year-over-year growth.
Handpiece sales and pricing: 9,400 handpieces sold in Q4 2025 at an average price of $3,340, reflecting a 5% sequential price increase.
International revenue growth: International revenue grew by 25% year-over-year in Q4 2025, reaching $9.8 million.
Sales team realignment: Commercial team reorganized into an integrated regional structure with clinical and sales functions reporting to a common regional leader.
Launch team formation: A dedicated launch team was created to focus on new system placements, aiming to improve launch consistency and accelerate customer value.
Pricing discipline: Eliminated bulk purchase discounts for handpieces, leading to better alignment of handpiece sales with procedure volumes and improved average selling prices.
Long-term growth strategy: Focus on increasing procedure volume, expanding margins, achieving profitability, and gaining market share.
2026 financial guidance: Revenue guidance set at $390M-$410M, representing 27%-33% growth, with a focus on sustainable growth and profitability by Q4 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Realignment and Launch Team Formation: The realignment of the commercial team and the creation of a dedicated launch team have caused short-term disruptions, including changes in account coverage and fewer tenured resources in the field. This transition period may temporarily impact customer relationships and operational efficiency.
Pricing Discipline on Handpieces: The elimination of bulk purchase discounts for handpieces has led to lower-than-expected revenue in the short term. This change may also strain customer relationships accustomed to previous pricing practices.
Gross Margin Decline: Gross margin for Q4 2025 decreased to 60.6% from 64% in Q4 2024, driven by lower U.S. consumable revenue and a one-time voluntary field action. This decline could impact profitability.
Increased Operating Expenses: Operating expenses rose to $77.4 million in Q4 2025 from $63.4 million in Q4 2024, reflecting higher costs for commercial expansion, innovation, and clinical trials. This increase contributes to a higher net loss and may pressure financial sustainability.
Net Loss and Adjusted EBITDA: Net loss for Q4 2025 increased to $29.8 million from $18.9 million in Q4 2024, and adjusted EBITDA loss widened to $19 million from $10.3 million. These losses highlight ongoing financial challenges.
Tariff Expenses Impacting Gross Margin: Projected tariff expenses for 2026 are expected to increase to $5-6 million from $1.3 million in 2025, creating a 100 basis point headwind to gross margin.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: Full year 2026 total revenue is expected to be in the range of $390 million to $410 million, representing growth of approximately 27% to 33% compared to 2025. This includes international revenue projected to be $50 million to $51 million.
2026 U.S. Procedures: Total U.S. procedures are expected to be in the range of 60,000 to 64,000, representing growth of approximately 39% to 48%.
Handpiece Revenue and Pricing: Handpiece unit sales are expected to align closely with procedure volumes, resulting in reduced handpiece revenue. However, this is offset by an increase in U.S. handpiece average selling prices, estimated to be $3,500 in 2026.
Gross Margin for 2026: Full year 2026 gross margin is expected to be approximately 65%, including $5 million to $6 million of tariff expenses, which represent a 100 basis point headwind.
Operating Expenses for 2026: Full year 2026 operating expenses are expected to total $350 million, representing a 17% increase compared to 2025.
Adjusted EBITDA for 2026: Full year 2026 adjusted EBITDA loss is expected to be in the range of $30 million to $17 million, with positive EBITDA anticipated in the fourth quarter of 2026.
First Quarter 2026 Guidance: Total U.S. procedures are expected to be in the range of 12,000 to 12,800, representing growth of 29% to 37%. Total revenues for the first quarter of 2026 are expected to be $79 million to $82 million, representing growth of 14% to 19%. This includes U.S. system revenue of approximately $20 million and $10 million of international revenue.
Second Half 2026 Procedure Growth: Procedures are expected to accelerate, reaching growth of over 50% in the second half of 2026 compared to fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the unexpected softness in handpiece sales during Q4?
A:The softness was due to two dynamics: destocking to establish part levels for accounts based on usage and the impact of bulk purchase discounts influencing customer behavior. The company decided to discontinue bulk purchase discounts, which led to a reduction in inventory and an increase in ASP to about $3,340. This change is expected to improve revenue predictability and align shipments with procedure volumes.
Q:Why is the 2026 guidance back-end loaded, and what gives confidence in the back-half benefit?
A:The back-end loading is due to the sales force maturing into the new alignment and rebuilding customer relationships. The company believes that having dedicated teams for procedure growth and launches will pay dividends later in the year. They plan to provide more details in the upcoming investor conference.
Q:What gives confidence in achieving a 1:1 handpiece-to-procedure ratio in 2026?
A:Historically, handpiece sales were 108%-115% of procedure volume, but the company is now modeling a 1:1 ratio even with an increase in the installed base by a couple of hundred systems. Recent changes in business practices have shown alignment between handpiece sales and procedures, supporting the 1:1 ratio.
Q:What was the field action in Q4, and will it impact future quarters?
A:The field action was a one-time, nonrecurring event related to compatibility between the handpiece and the system. It involved a field upgrade with no patient safety issues. The cost was approximately $1.5 million, impacting gross margin by 240 basis points, but it will not affect future quarters.
Q:Are there concerns about customer dissatisfaction or reduced utilization due to ending bulk purchase discounts?
A:The company has not observed customer dissatisfaction or reduced utilization. Some customers waited to see if discounts would return, but ordering patterns have normalized. The company believes procedure growth is not related to bulk discounts and is focused on disciplined pricing.
Q:What is the status and impact of the sales force realignment?
A:The sales force realignment involved creating dedicated launch teams and reallocating experienced personnel to ensure successful system launches. This caused some disruption as new relationships are being built, but the company believes it will improve execution and procedure growth in the long term.
Q:What is the expected ASP for systems in 2026, and how does it compare to 2025?
A:The company expects the ASP for systems to be flat to up in 2026 compared to 2025. The Q4 ASP was $425,000, and the company is modeling a slight increase in ASP for the upcoming year.
Q:What is the underlying demand for procedures, and are there any concerns about the competitive landscape?
A:Procedure growth was nearly 70% year-over-year in Q4, indicating strong demand. The company does not see competitive dynamics, such as PAE, significantly impacting their market. They plan to focus on procedure growth and provide more transparency on their value proposition.
Q:Why were changes to customer ordering practices and sales incentives made now?
A:The changes were made to eliminate unhealthy practices like bulk discounts, which created lumpy sales and impacted margins. The company prioritized improving ASP and establishing stable revenue patterns, which are foundational for long-term profitability.
Q:What is the company's strategy for market development and patient education?
A:The company plans to improve awareness of Aquablation's value proposition through targeted education programs for both patients and clinicians. They aim to take share from the 400,000 annual surgical BPH procedures and focus on disciplined, cost-effective marketing efforts.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing why the changes to customer ordering practices and sales incentives were not staged over time, instead opting for an immediate shift. Additionally, while they expressed confidence in achieving a 1:1 handpiece-to-procedure ratio, they did not provide detailed evidence or data to fully substantiate this claim.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BPH platform
Cancer trial
Cash cash
Day tomorrow
HYDRO system
Handpieces unit
IPO year
IV Prostate
Investor Day
Prostate Cancer
Water IV
accountability
afternoon PROCEPT
alignment
chapter
customer
discipline
discount
disruption sale
end
field
financials
handpiece unit
implementation
improvement handpiece
increase handpiece
inventory target
launch transition
practice change
purchase
realignment
reduction handpiece
sale procedure
structure
success
technology
term disruption
unit sale
vision
PRCT Transcript
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call indicates strong financial performance with optimistic guidance, including projected revenue growth of 27%-33% for 2026. Despite some challenges like flat procedures in Q1 and a prudent Q2 guidance, the company expects significant growth in the latter half of 2026. The strategic focus on international expansion and new initiatives, coupled with a positive outlook on gross margin and EBITDA, supports a positive sentiment. Given the company's market cap, the stock price is likely to see a moderate positive movement of 2% to 8% over the next two weeks.
PROCEPT BioRobotics Corporation (PRCT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-6
PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call reveals a mixed performance with strong revenue growth and improved gross margins, but significant concerns arise from increased losses, higher operating expenses, and weak Q4 handpiece sales. While guidance for 2026 shows potential, the immediate impact of discontinuing bulk discounts, increased ASP, and the sales force realignment creates uncertainty. The Q&A session highlights management's confidence in future growth but lacks concrete evidence for some claims. Given the market cap and these factors, a negative stock price reaction is expected.
PRCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
